Previous Close | 1.6000 |
Open | 1.5950 |
Bid | 1.5700 x 100 |
Ask | 1.6100 x 600 |
Day's Range | 1.5900 - 1.6500 |
52 Week Range | 1.0400 - 2.8550 |
Volume | |
Avg. Volume | 918,452 |
Market Cap | 107.694M |
Beta (5Y Monthly) | 1.02 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.90 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across ma
- Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date - - CytomX-retains US co-commercialization and economic rights for select programs - SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milest